Evidence map›Paper›PMID 27445299›Full record

ArticleJournal of applied physiology (Bethesda, Md. : 1985)2016

Fibroblast growth factor 21 is required for beneficial effects of exercise during chronic high-fat feeding.

Christine Loyd, I Jack Magrisso, Michael Haas, Sowmya Balusu, Radha Krishna, Nobuyuki Itoh, Darleen A Sandoval, Diego Perez-Tilve, Silvana Obici, Kirk M Habegger

Open access · bronzeAbstract read
In one paragraph

Article in Journal of applied physiology (Bethesda, Md. : 1985), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Hepatokines as a Molecular Transducer of Exercise.Journal of clinical medicine · 2021
    Review
  14. Article
  15. Article
  16. Advances in Biological Functions and Clinical Studies of FGF21.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021
    Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Christine LoydComprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes & and Metabolism, University of Alabama at Birmingham, Birmingham, Alabama; Metabolic Disease Institute, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Cincinnati, Cincinnati, Ohio.
I Jack MagrissoMetabolic Disease Institute, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Cincinnati, Cincinnati, Ohio.
Michael HaasMetabolic Disease Institute, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Cincinnati, Cincinnati, Ohio.
Sowmya BalusuMetabolic Disease Institute, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Cincinnati, Cincinnati, Ohio.
Radha KrishnaMetabolic Disease Institute, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Cincinnati, Cincinnati, Ohio.
Nobuyuki ItohDepartment of Genetic Biochemistry, Kyoto University Graduate School of Pharmaceutical Sciences, Kyoto, Japan;
Darleen A SandovalMetabolic Disease Institute, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Cincinnati, Cincinnati, Ohio.
Diego Perez-TilveMetabolic Disease Institute, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Cincinnati, Cincinnati, Ohio.
Silvana ObiciMetabolic Disease Institute, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Cincinnati, Cincinnati, Ohio.
Kirk M HabeggerComprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes & and Metabolism, University of Alabama at Birmingham, Birmingham, Alabama; UAB Center for Exercise Medicine, University of Alabama at Birmingham, Birmingham, Alabama; kirkhabegger@uabmc.edu.ORCID 0000-0002-0342-5480
University of Cincinnati · USUniversity of Alabama at Birmingham · USKyoto University · JP

Funding

Why is the prevalence of obesity so high in U.S. Southern States? Regional predictors of BMI and obesity treatment response.P30DK056336 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BARBARA A GOWER · 2000 to 2026
$31.9M
Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DAVID P OLSON · 2013 to 2026
$24.3M
University of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Kirk Michael Habegger · 2013 to 2026
$19.5M
Interdisciplinary Training in Pathobiology and Rehabilitation Medicine.T32HD071866 · NICHD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI JAMES RIMMER, Anna E. Thalacker-Mercer · 2012 to 2026
$4.8M
Duodenal nutrient exclusion enhances glucose metabolism via CNS regulationK01DK098319 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HABEGGER, KIRK MICHAEL · 2014 to 2016
$456k
NICHD NIH HHS T32 HD071866NIDDK NIH HHS K01 DK098319NIDDK NIH HHS P30 DK020572NIDDK NIH HHS P30 DK056336NIDDK NIH HHS P30 DK079626
6 · The paper itself

Abstract

Exercise is an effective therapy against the metabolic syndrome. However, the molecular pathways underlying the advantageous effects of exercise are elusive. Glucagon receptor signaling is essential for exercise benefits, and recent evidence indicates that a downstream effector of glucagon, fibroblast growth factor 21 (FGF21), is implicated in this response. Therefore, we tested the hypothesis that FGF21 action is necessary in mediating metabolic effects of exercise. We utilized acute exhaustive treadmill exercise in Wistar rats to identify a putative, concomitant increase in plasma glucagon and FGF21 with the increase in glucose and lactate following exercise. To test the necessity of FGF21 action in the exercise response, we exposed FGF21 congenitally deficient mice (Fgf21(-/-)) and their wild-type (Wt) littermates to chronic high-fat (HF) feeding and inoperable (sedentary) or operable (exercise) voluntary running wheels. Physiological tests were performed to assess the role of FGF21 in the beneficial effect of exercise on glucose metabolism. Wt and Fgf21(-/-) littermates exhibited similar running behavior, and exercise was effective in suppressing weight and fat mass gain and dyslipidemia independently of genotype. However, exercise failed to positively affect hepatic triglyceride content and glucose tolerance in HF diet-fed Fgf21(-/-) mice. Furthermore, Fgf21(-/-) mice exhibited an impaired adaptation to exercise training, including reduced AMP-activated protein kinase activity in skeletal muscle. This study demonstrates that FGF21 action is necessary to achieve the full metabolic benefits of exercise during chronic HF feeding.

Indexed as

Diet, High-FatAnimalsBlood GlucoseBody WeightChronic DiseaseExercise TherapyFibroblast Growth FactorsMaleMiceMice, KnockoutObesityPhysical Conditioning, AnimalRatsRats, WistarTreatment OutcomeBlood Glucosefibroblast growth factor 21Fibroblast Growth FactorsAMP-activated protein kinaseexercisefibroblast growth factor 21glucose toleranceinsulin actionlipid homeostasis

Identifiers

PMID27445299
PMCPMC5142257
OpenAlexW2497460640

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.